JP2012510461A - Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 - Google Patents

Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 Download PDF

Info

Publication number
JP2012510461A
JP2012510461A JP2011538092A JP2011538092A JP2012510461A JP 2012510461 A JP2012510461 A JP 2012510461A JP 2011538092 A JP2011538092 A JP 2011538092A JP 2011538092 A JP2011538092 A JP 2011538092A JP 2012510461 A JP2012510461 A JP 2012510461A
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
nos
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011538092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012510461A5 (enExample
Inventor
ルジユヌ，パスカル
ブリニヨー，パトリシア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40578382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012510461(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2012510461A publication Critical patent/JP2012510461A/ja
Publication of JP2012510461A5 publication Critical patent/JP2012510461A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011538092A 2008-11-28 2009-11-27 Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 Withdrawn JP2012510461A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08291116A EP2191840A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP08291116.5 2008-11-28
PCT/IB2009/055389 WO2010061357A1 (en) 2008-11-28 2009-11-27 Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015107404A Division JP6148696B2 (ja) 2008-11-28 2015-05-27 Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤

Publications (2)

Publication Number Publication Date
JP2012510461A true JP2012510461A (ja) 2012-05-10
JP2012510461A5 JP2012510461A5 (enExample) 2012-11-22

Family

ID=40578382

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011538092A Withdrawn JP2012510461A (ja) 2008-11-28 2009-11-27 Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤
JP2015107404A Active JP6148696B2 (ja) 2008-11-28 2015-05-27 Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤
JP2017037860A Pending JP2017141233A (ja) 2008-11-28 2017-03-01 Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015107404A Active JP6148696B2 (ja) 2008-11-28 2015-05-27 Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤
JP2017037860A Pending JP2017141233A (ja) 2008-11-28 2017-03-01 Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤

Country Status (32)

Country Link
US (1) US9259406B2 (enExample)
EP (2) EP2191840A1 (enExample)
JP (3) JP2012510461A (enExample)
KR (1) KR101733252B1 (enExample)
CN (1) CN102264385B (enExample)
AR (1) AR074219A1 (enExample)
AU (1) AU2009321249B2 (enExample)
BR (1) BRPI0921864B1 (enExample)
CA (1) CA2744990C (enExample)
CL (1) CL2011001254A1 (enExample)
CO (1) CO6440557A2 (enExample)
CR (1) CR20110280A (enExample)
EA (1) EA026867B1 (enExample)
EC (1) ECSP11011062A (enExample)
HN (1) HN2011001417A (enExample)
IL (1) IL213116B (enExample)
MA (1) MA32896B1 (enExample)
ME (1) ME01136B (enExample)
MX (1) MX342625B (enExample)
MY (1) MY164577A (enExample)
NI (1) NI201100105A (enExample)
NZ (1) NZ593027A (enExample)
PA (1) PA8850101A1 (enExample)
PE (1) PE20120340A1 (enExample)
SG (1) SG171820A1 (enExample)
SV (1) SV2011003924A (enExample)
TN (1) TN2011000232A1 (enExample)
TW (1) TWI454260B (enExample)
UA (1) UA107069C2 (enExample)
UY (1) UY32263A (enExample)
WO (1) WO2010061357A1 (enExample)
ZA (1) ZA201103925B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015530399A (ja) * 2012-09-25 2015-10-15 モルフォシス エージー 組み合わせ及びその使用

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0816777B2 (ja) 1988-10-13 1996-02-21 富士写真フイルム株式会社 画像形成方法
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
CA2796464C (en) * 2010-04-16 2021-08-03 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
ES2617446T3 (es) 2010-09-27 2017-06-19 Morphosys Ag Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
TW201522378A (zh) * 2013-10-31 2015-06-16 Sanofi Sa 用於治療人類癌症的特異性抗ｃｄ３８抗體
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2016022589A2 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
BR112017004614A2 (pt) 2014-09-09 2018-02-27 Janssen Biotech, Inc. terapias de combinação com anticorpos anti-cd38
EA202092609A1 (ru) 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
CN108136218B (zh) 2015-05-20 2022-12-13 詹森生物科技公司 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
NZ777133A (en) 2015-06-22 2025-05-02 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
RS61651B1 (sr) 2015-11-03 2021-04-29 Janssen Biotech Inc Potkožne formulacije anti-cd38 antitela i njihova upotreba
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN109689690B (zh) 2016-07-15 2023-10-03 武田药品工业株式会社 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
WO2019130228A1 (en) * 2018-01-01 2019-07-04 Orbicular Pharmaceutical Technologies Pvt. Ltd., Stable liquid compositions of melphalan
CA3088199A1 (en) 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
EP3856226A1 (en) 2018-09-28 2021-08-04 President and Fellows of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
MX2021011181A (es) 2019-03-15 2022-01-19 Morphosys Ag Anticuerpos anti-cd38 y sus composiciones farmacéuticas para el tratamiento de la enfermedad autoinmune mediada por autoanticuerpos.
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
AU2020397170A1 (en) 2019-12-05 2022-07-21 Sanofi-Aventis U.S. Llc Formulations of anti-CD38 antibodies for subcutaneous administration
WO2022152823A1 (en) 2021-01-14 2022-07-21 Morphosys Ag Anti-cd38 antibodies and their uses
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524587A (ja) * 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
WO2008047242A2 (en) * 2006-10-19 2008-04-24 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
JP2008533977A (ja) * 2005-03-23 2008-08-28 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
GB0221574D0 (en) 2002-09-17 2002-10-23 Isis Innovation Treatments
ES2541436T3 (es) 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
NZ576122A (en) 2006-09-26 2012-09-28 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
US20080092384A1 (en) * 2006-10-16 2008-04-24 Schaake Mark D Installation of Middle Bearing for a Crankshaft
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524587A (ja) * 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
JP2008533977A (ja) * 2005-03-23 2008-08-28 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
WO2008047242A2 (en) * 2006-10-19 2008-04-24 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015530399A (ja) * 2012-09-25 2015-10-15 モルフォシス エージー 組み合わせ及びその使用

Also Published As

Publication number Publication date
CA2744990A1 (en) 2010-06-03
CN102264385B (zh) 2015-05-20
MX342625B (es) 2016-10-06
TN2011000232A1 (en) 2012-12-17
HN2011001417A (es) 2014-01-13
EP2191840A1 (en) 2010-06-02
AU2009321249A1 (en) 2010-06-03
JP6148696B2 (ja) 2017-06-14
KR101733252B1 (ko) 2017-05-08
JP2017141233A (ja) 2017-08-17
EA026867B1 (ru) 2017-05-31
CO6440557A2 (es) 2012-05-15
CL2011001254A1 (es) 2012-01-27
IL213116A0 (en) 2011-07-31
JP2015205890A (ja) 2015-11-19
PE20120340A1 (es) 2012-04-17
US9259406B2 (en) 2016-02-16
SG171820A1 (en) 2011-07-28
EP2370094A1 (en) 2011-10-05
EA201100864A1 (ru) 2011-12-30
ME01136B (me) 2013-03-20
NI201100105A (es) 2011-12-13
CN102264385A (zh) 2011-11-30
AR074219A1 (es) 2010-12-29
TW201023855A (en) 2010-07-01
MY164577A (en) 2018-01-15
MA32896B1 (fr) 2011-12-01
US20110274686A1 (en) 2011-11-10
SV2011003924A (es) 2011-10-07
UY32263A (es) 2010-06-30
UA107069C2 (uk) 2014-11-25
AU2009321249B2 (en) 2016-06-09
BRPI0921864A2 (pt) 2018-10-09
ZA201103925B (en) 2012-09-26
ECSP11011062A (es) 2011-07-29
BRPI0921864B1 (pt) 2022-11-16
WO2010061357A1 (en) 2010-06-03
HK1164165A1 (en) 2012-09-21
CA2744990C (en) 2019-05-07
TWI454260B (zh) 2014-10-01
PA8850101A1 (es) 2010-07-27
KR20110096550A (ko) 2011-08-30
NZ593027A (en) 2012-12-21
CR20110280A (es) 2011-09-20
MX2011005670A (es) 2011-09-30
IL213116B (en) 2018-11-29

Similar Documents

Publication Publication Date Title
JP6148696B2 (ja) Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤
JP6215429B2 (ja) Ｃｄ３８を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ
JP6072854B2 (ja) Ｃｄ３８を特異的に認識する抗体とシタラビンを含有する抗腫瘍性組合せ剤
JP6130871B2 (ja) Ｃｄ３８を特異的に認識する抗体とビンクリスチンとを含有する抗腫瘍組合せ
HK1164165B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
HK1164152A (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine
HK1164154B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide
HK1164153B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140317

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150527

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150618